Deficit spending

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

Retrieved on: 
måndag, juni 3, 2024
Agitation, Dementia, Public, Caregiver, Patient, Mental health, FCA, Deficit spending, Therapy, Research, Life, AFA, Alzheimer's disease, Disability, Education, Myenteric plexus, Disease, National Alliance, Central nervous system, Family Caregiver Alliance, Organization, Quality of life, Brain, Stroke, CNS, Residential care

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation.

Key Points: 
  • Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline, and behavioral and psychological symptoms including agitation.
  • Axsome is committed to making a meaningful difference in the lives of those affected by Alzheimer’s disease and other central nervous system disorders.
  • In observance of Alzheimer’s & Brain Awareness Month, One World Trade Center, Axsome’s corporate headquarters in New York City, will be illuminated in purple, the color for Alzheimer’s disease awareness, on June 21, 2024, through the building’s Spireworks program.
  • Its mission is to build partnerships in research, advocacy, and innovation to make life better for family caregivers.

Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹

Retrieved on: 
torsdag, maj 30, 2024
GBL, FOS, University, Risk, Prevalence, Trial of the century, Ageing, Dementia, Health, Name, Research, Geriatrics, General practitioner, Woman, Brain, Deficit spending, MCI, Memory, Dietary supplement

GBL has recently launched GBL-Memory1, its first nutraceutical product, to consumers in the UK and Germany.

Key Points: 
  • GBL has recently launched GBL-Memory1, its first nutraceutical product, to consumers in the UK and Germany.
  • The prevalence of cognitive impairment, including mild cognitive impairment (MCI) and dementia, increases with age, with the risk doubling every five years after the age of 65.
  • It is suggested that 5-7% of individuals aged 60 or older experience significant cognitive decline each year.
  • The research used the Clinical Memory Scale to assess the benefits of taking the supplement, which contribute to the improvement in total memory.

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
onsdag, maj 29, 2024
Neuroscience, FDA, Drug development, Pediatrics, Drug discovery, Distinguishing, Mental health, Research, Therapy, ALS, Pharmacology, Human, Translational research, Ageing, Multiple sclerosis, Myenteric plexus, CNS, Division, Cognition, University, Clinical trial, DSM-IV codes, Regulatory affairs, Genetics, Associate, SAB, Schizophrenia, CIAS, Patient, Organization, NIMH, Duke University Hospital, Biomarker, Abstract, Brain, Deficit spending, Pharmaceutical industry

NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).

Key Points: 
  • NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).
  • "At Kynexis, we are committed to restoring brain function to enable a better life for people with schizophrenia,” said Kees Been, Chief Executive Officer at Kynexis.
  • Robert Schwarcz, Ph.D., is a Scientific Co-founder of Kynexis and Professor of Psychiatry, Pharmacology and Pediatrics at the University of Maryland Baltimore.
  • Based on these insights, he co-founded Kynexis to develop fundamentally new interventions for the prevention and treatment of brain dysfunctions in humans.

New Study Findings Show Statistically Significant Weight Loss for Medicare-Eligible Population in the Wondr Program

Retrieved on: 
onsdag, maj 29, 2024
Diabetes, Cardiovascular disease, Doctor of Philosophy, Medicare, Obesity, University, Overweight, Male, Health, Frontiers Media, Research, Cancer, Weight loss, FACSM, Curriculum, Frailty, Deficit spending, Quality of life, Female, Dietary supplement

“This study demonstrates that Wondr can be used to engage older populations in weight loss,” said Renee Rogers, PhD, FACSM, lead author, senior scientist, University of Kansas Medical Center, and Wondr Health instructor.

Key Points: 
  • “This study demonstrates that Wondr can be used to engage older populations in weight loss,” said Renee Rogers, PhD, FACSM, lead author, senior scientist, University of Kansas Medical Center, and Wondr Health instructor.
  • The purpose of this study was to evaluate Wondr as a more accessible digital intervention for weight loss in older adults.
  • The average weight loss was statistically significant at nearly 7 pounds at 15.5 weeks.
  • Weight loss was significantly greater in male (8.36 pounds) versus female participants (6.33 pounds), and a longer engagement in the program was associated with greater weight loss.

Leisure Care Creates More Connected Lives for Residents with Nationwide Rollout of Rendever

Retrieved on: 
tisdag, maj 21, 2024
Partnership, Caregiver burden, VR, Ageing, Animal, Virtual reality, Deficit spending, Social isolation, Tourism

Similarly to Rendever, Leisure Care is reimagining and reinventing the aging experience to ensure older adults have the most fulfilling, rewarding, and productive opportunities possible.

Key Points: 
  • Similarly to Rendever, Leisure Care is reimagining and reinventing the aging experience to ensure older adults have the most fulfilling, rewarding, and productive opportunities possible.
  • With the implementation of Rendever’s flagship resident engagement platform at Leisure Care communities, a world of endless possibilities opens up to residents.
  • Leisure Care uses the VR technology to help its residents, particularly those with cognitive impairment, remember, rediscover, and reinvigorate their lives.
  • “Working with Rendever since 2020, we’ve seen firsthand how impactful this technology has been for our residents.

BrainCheck Plan Wins "Care Management Innovation Award" in 8th Annual MedTech Breakthrough Awards

Retrieved on: 
torsdag, maj 9, 2024
Model, Medtech, FDA, DNP, FAAN, Dementia, Risk, Professor, Health, DSM-IV codes, MD, Doctor of Philosophy, Alzheimer's disease, Disease, Patient, RN, Caregiver, Assessment, Emory University, Quality of life, Deficit spending, Nursing

AUSTIN, Texas , May 9, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, today announced that its care planning solution, BrainCheck Plan™, was selected as the winner of the "Care Management Innovation Award" in the 8th annual MedTech Breakthrough Awards program, which recognizes the top companies, people, platforms, and products in the health, fitness, and medical technology industries. This year's program attracted thousands of nominations from more than 18 countries worldwide.

Key Points: 
  • "Following information provided by BrainCheck Screen™ and Assess™, our comprehensive care planning is the critical next step for providers, patients and caregivers," said Kim Rodriguez, CEO of BrainCheck.
  • "The evolution of the BrainCheck platform reflects our customers' evolving needs, and this recognition of our product further validates the value of our technology."
  • "With BrainCheck Plan, we can quickly customize care plans and document recommendations for patients and caregivers, based on individual needs.
  • BrainCheck Plan is equipping providers with an innovative solution to support the journey for patients and their families."

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Retrieved on: 
torsdag, maj 9, 2024
Disorder, Common, Risk, GC, Overweight, Trial of the century, Adrenocorticotropic hormone, Hyperlipidemia, Associate, Deficit spending, Hydrocortisone, Neurocrine Biosciences, White matter, Food, Oklahoma State University–Stillwater, Cognition, Psychology, Testosterone, Male, Literature, Brain, DSM-IV codes, A4, SAN, GCS, CAH, Acne, Safety, Glucocorticoid, Research, Depression, Congenital adrenal hyperplasia, Osteopenia, Anxiety, Division, Hirsutism, Androstenedione, Psychiatry, Psychosis, Hypertension, Metabolism, Poster, Pharmaceutical industry

The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.

Key Points: 
  • The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
  • These new data were presented at oral presentations and poster sessions at the American Association of Clinical Endocrinology 2024 Annual Meeting in New Orleans.
  • Despite supraphysiologic GC dosing, levels of adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione (A4) were elevated at baseline, with levels of testosterone (females) and A4/testosterone (males) also elevated.
  • The data from both studies supported two New Drug Applications submitted to the U.S. Food and Drug Administration in April 2024.

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Sale, TNF, Phase, DSM-IV codes, Patient, MUC4, CD47, Pacific Rim, CTLA4, LAG3, Research, Tumor microenvironment, Conference, Downregulation and upregulation, Disease, Exercise, Chemistry, SRC, Macrophage, BOCA, TIGIT, Treatment-resistant depression, Neuroinflammation, Neoplasm, Deficit spending, TME, Pharmaceutical industry

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.
  • INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Financial Results for the First Quarter Ended March 31, 2024:
    Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.
  • Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
måndag, maj 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

SECU Foundation Awards MemoryCare $250,000 to Expand Dementia Care in Rural Western North Carolina

Retrieved on: 
måndag, maj 6, 2024
Education, Housing, Health, Deficit spending, Dementia, Patient, Medicine, Caregiver, National Credit Union Administration, NCUA, ATM, Hospital

ASHEVILLE, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- SECU Foundation has awarded $250,000 to MemoryCare for the programmatic expansion of dementia care and in-home clinical and care management services in rural Western North Carolina.

Key Points: 
  • ASHEVILLE, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- SECU Foundation has awarded $250,000 to MemoryCare for the programmatic expansion of dementia care and in-home clinical and care management services in rural Western North Carolina.
  • This grant follows two previous awards that SECU Foundation provided to the non-profit to address the health and well-being of the people living in this 18-county region.
  • Their family-focused work is incredibly powerful and the impact is beyond measure,” said SECU Foundation Executive Director Jama Campbell.
  • Since 2004, SECU Foundation has made a collective financial commitment of over $258 million for initiatives to benefit North Carolinians statewide.